Search
Influenza A virus A/Switzerland/9715293/2013 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB11035ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen
go.drugbank.com/drugs/DB11037ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11040ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11041ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11042ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11046ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
99mTc-glucarate
go.drugbank.com/drugs/DB05810Investigational99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
Norbixin
go.drugbank.com/drugs/DB15201ExperimentalNorbixin is under investigation in clinical trial NCT03820245 (Effect of Short-term Annatto Carotenoids Supplementation on Oxidative Stress Status in Healthy Individuals).
Batoclimab
go.drugbank.com/drugs/DB16104InvestigationalBatoclimab is under investigation in clinical trial NCT04428255 (A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP).
Lepunafusp alfa
go.drugbank.com/drugs/DB19011InvestigationalLepunafusp alfa is under investigation in clinical trial NCT04453085 (An Extension Study of JR-171-101 Study in Patients With MPS I).